Ticker > Company >

Kwality Pharma share price

Kwality Pharmaceuticals Ltd.

BSE: 539997 SECTOR: Pharmaceuticals & Drugs  48.6 K   360   13

969.30
+1.95 (0.20%)
BSE: 11 Sep 04:01 PM

Price Summary

Today's High

₹ 988

Today's Low

₹ 940

52 Week High

₹ 1235

52 Week Low

₹ 596.05

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1005.76 Cr.

Enterprise Value

1103.92 Cr.

No. of Shares

1.04 Cr.

P/E

23.14

P/B

3.63

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  266.94

CASH

14.29 Cr.

DEBT

112.45 Cr.

Promoter Holding

54.83 %

EPS (TTM)

₹  41.88

Sales Growth

20.52%

ROE

16.28 %

ROCE

18.3%

Profit Growth

66.32 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year20.52%
3 Year-6.72%
5 Year21.7%

Profit Growth

1 Year66.32%
3 Year-30.74%
5 Year36.46%

ROE%

1 Year16.28%
3 Year12.56%
5 Year32.97%

ROCE %

1 Year18.3%
3 Year14.73%
5 Year33.58%

Debt/Equity

0.4243

Price to Cash Flow

19.06

Interest Cover Ratio

6.4897

CFO/PAT (5 Yr. Avg.)

1.02333092630848

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 54.83 0.00
Mar 2025 54.83 0.00
Dec 2024 54.83 0.00
Sep 2024 54.83 0.00
Jun 2024 54.83 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 23.3029576158055% in the last 5 years.
  • Company’s PEG ratio is 0.348995691498084.
  • The company has an efficient Cash Conversion Cycle of 56.5878 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.02333092630848.
  • The company has a high promoter holding of 54.83%.

 Limitations

  • The company has shown a poor profit growth of -30.7366272902914% for the Past 3 years.
  • The company has shown a poor revenue growth of -6.72157301004935% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 80.08 90.03 84.41 115.68 111.48
Total Expenditure 62.72 70.35 66.9 89.78 87.29
Operating Profit 17.36 19.68 17.51 25.9 24.19
Other Income 0.28 0.22 0.66 0.77 0.38
Interest 2.48 2.71 2.2 2.49 2.76
Depreciation 4.02 4.61 4.55 5.08 4.76
Exceptional Items 0 0 0 0 0
Profit Before Tax 11.14 12.58 11.41 19.09 17.04
Tax 2.77 4.1 2.87 4.59 5.11
Profit After Tax 8.37 8.48 8.54 14.5 11.93
Adjusted EPS (Rs) 8.06 8.18 8.23 13.97 11.5

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 261.5 456.13 250.99 307.17 370.2
Total Expenditure 232.24 284.41 190.12 240.54 289.75
Operating Profit 29.26 171.72 60.88 66.63 80.44
Other Income 1.59 3.51 2.94 1.83 1.92
Interest 2.62 2.92 6.61 10.39 9.88
Depreciation 6.44 10.64 14.92 19.51 18.26
Exceptional Items 0 0 -16.53 -7.1 0
Profit Before Tax 21.8 161.67 25.76 31.47 54.23
Tax 6.38 41.63 6.29 7.48 14.34
Net Profit 15.42 120.05 19.47 23.98 39.89
Adjusted EPS (Rs.) 14.86 115.69 18.76 23.11 38.44

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 10.38 10.38 10.38 10.38 10.38
Total Reserves 52.13 172.18 191.65 215.57 255.47
Borrowings 18.26 20.29 27.3 19.56 15.12
Other N/C liabilities 9.82 1.03 1.31 0.19 -1.36
Current liabilities 78.15 138.8 125.94 151.85 169.51
Total Liabilities 168.75 342.68 356.58 397.55 449.11
Assets
Net Block 55.52 90.77 119.57 138.18 144.47
Capital WIP 2.89 12.15 14.29 0 0
Intangible WIP 0 0 0 0 0
Investments 4.28 3.55 3.55 3.55 3.55
Loans & Advances 0.17 8.11 10.71 12.44 16.19
Other N/C Assets 0 0.78 0.93 0 0
Current Assets 105.88 227.32 207.52 243.38 284.9
Total Assets 168.75 342.68 356.58 397.55 449.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 21.8 161.67 25.76 31.47 54.23
Adjustment 8.98 13.51 20.91 36.61 27.97
Changes in Assets & Liabilities 1.96 -74.59 1.67 -23.43 -13.64
Tax Paid -6.38 -41.35 -6.16 -1.3 -15.79
Operating Cash Flow 26.36 59.24 42.19 43.35 52.77
Investing Cash Flow -23.2 -62.98 -48.44 -26.4 -28.13
Financing Cash Flow 0.83 5.66 0.99 -17.4 -14.44
Net Cash Flow 3.99 1.93 -5.26 -0.45 10.2

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 54.83 54.83 54.83 54.83 54.83
aditya arora 11.95 11.95 11.95 11.95 11.95
ajay arora 13.59 13.59 13.59 13.59 13.59
anju arora 1.31 1.31 1.31 1.31 1.31
geeta arora 1.07 1.07 1.07 1.07 1.07
jugal kishore huf 0.89 0.89 0.89 0.89 0.89
ramesh arora 26.01 26.01 26.01 26.01 26.01
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 45.17 45.17 45.17 45.17 45.17
deepak bansal 10.63 10.63 10.63 10.63 10.63
dheeraj kumar lohia 1.92 1.92 1.91 1.91 1.89
investor education and pr... - - 0.97 0.97 0.97
jani bhasha shaik 1.45 1.45 1.45 1.45 1.45
kadayam ramnathan bharat 1.88 1.88 1.88 1.98 1.98
manohar devabhaktuni 4.98 4.98 4.98 4.98 4.98
onkar singh 1.02 1.06 1.06 1.08 1.09
investor education and pr... 0.97 0.97 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY22
Presentation FY2024

Company News

 No Latest News available for this company.Report us

Kwality Pharma Stock Price Analysis and Quick Research Report. Is Kwality Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Kwality Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Kwality Pharma has a PE ratio of 23.1449754653231 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Kwality Pharma has ROA of 9.4229% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Kwality Pharma has a Current ratio of 1.6808.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Kwality Pharma has a ROE of 16.2752%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Kwality Pharma has a Debt to Equity ratio of 0.4243 which means that the company has low proportion of debt in its capital.

  • Sales growth: Kwality Pharma has reported revenue growth of 20.5179% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Kwality Pharma for the current financial year is 21.7298357361081%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Kwality Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Kwality Pharma is Rs 41.8795. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Kwality Pharma in Ticker for free. Also, one can get the intrinsic value of Kwality Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Kwality Pharma FAQs

Q1. What is Kwality Pharma share price today?
Ans: The current share price of Kwality Pharma is Rs 969.3.

Q2. What is the market capitalisation of Kwality Pharma?
Ans: Kwality Pharma has a market capitalisation of Rs 1005.76487214 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Kwality Pharma?
Ans: The PE ratio of Kwality Pharma is 23.1449754653231 and the P/B ratio of Kwality Pharma is 3.63121564243633, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Kwality Pharma share?
Ans: The 52-week high share price of Kwality Pharma is Rs 1235, and the 52-week low share price of Kwality Pharma is Rs 596.05.

Q5. Does Kwality Pharma pay dividends?
Ans: Currently, Kwality Pharma does not pay dividends. Dividend yield of Kwality Pharma is around 0%.

Q6. What are the face value and book value of Kwality Pharma shares?
Ans: The face value of Kwality Pharma shares is Rs 10, while the book value per share of Kwality Pharma is around Rs 266.9354. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Kwality Pharma?
Ans: Kwality Pharma has a total debt of Rs 112.4452 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Kwality Pharma?
Ans: The ROE of Kwality Pharma is 16.2752% and ROCE of Kwality Pharma is 18.296%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Kwality Pharma a good buy for the long term?
Ans: The Kwality Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Kwality Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Kwality Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Kwality Pharma’s financials?
Ans: You can review Kwality Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Kwality Pharma
X